Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals CoTPE:6472 -2.76%81 EV-to-EBITDA is 16.49 as of Aug. 18, 2026, which is 9% above its 10-year median of 15.10. GuruFocus rates TPE:6472 with a GF Score™ of 81/100 and a GF Value™ of NT$744.19 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 734 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks worse than 60.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bora Pharmaceuticals Co's enterprise value is NT$66,314 Mil.
Bora Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NT$4,021 Mil. Therefore, Bora Pharmaceuticals Co's EV-to-EBITDA for today is 16.49.
The historical rank and industry rank for Bora Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:
TPE:6472'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.62 Med: 15.1 Max: 66.96
Current: 16.5
During the past 13 years, the highest EV-to-EBITDA of Bora Pharmaceuticals Co was 66.96. The lowest was 5.62. And the median was 15.10.
TPE:6472's EV-to-EBITDA is ranked worse than 60.08% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs TPE:6472: 16.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bora Pharmaceuticals Co (TPE:6472) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bora Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Bora Pharmaceuticals Co's share price for today is NT$404.50.
Bora Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$12.612.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's EV-to-EBITDA falls into.
Bora Pharmaceuticals Co's current Enterprise Value is NT$66,314 Mil.
Bora Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4,021 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (TPE:6472) has a EV-to-EBITDA of 16.49 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bora Pharmaceuticals Co. This is near median its historical median of 15.10. Over the past decade, Bora Pharmaceuticals Co's EV-to-EBITDA has ranged from 5.62 to 66.96. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #441 out of 734 companies in the Drug Manufacturers industry, placing it in the top 60.1%.
Is Bora Pharmaceuticals Co's EV-to-EBITDA too high?
Bora Pharmaceuticals Co's current EV-to-EBITDA of 16.49 is near median its 10-year median of 15.10. Over the past 10 years, this metric has ranged from a low of 5.62 to a high of 66.96. The Drug Manufacturers industry median EV-to-EBITDA is 13.44. Bora Pharmaceuticals Co's value of 16.49 is 22.7% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #441 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #441 out of 734 companies for EV-to-EBITDA. This places Bora Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. Bora Pharmaceuticals Co's value of 16.49 is 22.7% above this benchmark. Historically, Bora Pharmaceuticals Co's own EV-to-EBITDA has ranged from 5.62 to 66.96 over the past decade. While the company's 10-year median is 15.10 vs. the industry median of 13.44, Bora Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current EV-to-EBITDA of 16.49 is 22.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bora Pharmaceuticals Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current EV-to-EBITDA is 16.49, which is near median its own 10-year median of 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$744.19, compared to a current price of NT$404.50 — trading 45.6% below its estimated fair value. The current EV-to-EBITDA is 16.49, which is near median its 10-year median of 15.10 and 22.7% above the Drug Manufacturers industry median of 13.44. Bora Pharmaceuticals Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current EV-to-EBITDA is 16.49 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$404.50 is trading 45.6% below its estimated GF Value™ of NT$744.19.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
EV-to-EBITDA: 16.49 (near median its 10-year median of 15.10)
GF Value™: NT$744.19 vs. price of NT$404.50 (45.6% below fair value)
Industry Position: 22.7% above the Drug Manufacturers median (#441 of 734)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
81GF Score
Get the complete analysis for TPE:6472
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
